We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)
- Authors
Humbert, Marc; Kovacs, Gabor; Hoeper, Marius M; Badagliacca, Roberto; Berger, Rolf M F; Brida, Margarita; Carlsen, Jørn; Coats, Andrew J S; Escribano-Subias, Pilar; Ferrari, Pisana; Ferreira, Diogenes S; Ghofrani, Hossein Ardeschir; Giannakoulas, George; Kiely, David G; Mayer, Eckhard; Meszaros, Gergely; Nagavci, Blin; Olsson, Karen M; Pepke-Zaba, Joanna; Quint, Jennifer K
- Abstract
Patient associations are a valuable resource for managing patients, as they provide educational and emotional support, and can have positive effects on coping, confidence, and outlook.[846] It is recommended that PH centres collaborate with patient associations on initiatives to empower patients and improve the patient experience, addressing issues such as health literacy, digital skills, healthy lifestyles, mental health, and self-management. Mechanical circulatory support has become an established bridging tool to transplantation in patients with irreversible right HF, but is occasionally used as a bridge to recovery in patients with treatable causes and potentially reversible RV failure.[468] No general recommendations can be made regarding the indication for mechanical circulatory support, which needs to be individualized, considering patient factors and local resources.[469],[470] Long-term mechanical support analogous to left ventricular assist devices (LVADs) is not yet available for patients with PH and end-stage right HF. While the age-adjusted mortality of patients with the left heart phenotype seems to be similar to that of patients with classical PAH, patients with a cardiopulmonary phenotype and a low DLCO have a particularly high mortality risk.[77],[78],[161],[450],[451] As patients with cardiopulmonary comorbidities were under-represented in or excluded from PAH trials, no evidence-based treatment recommendations can be made for this patient population.
- Subjects
HEART failure; INTERSTITIAL lung diseases; PULMONARY hypertension; RESPIRATORY diseases; LUNG transplantation; HEART transplantation; SCIMITAR syndrome
- Publication
European Heart Journal, 2022, Vol 43, Issue 38, p3618
- ISSN
0195-668X
- Publication type
Article
- DOI
10.1093/eurheartj/ehac237